89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio11/29 13:00

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

89bio11/26 13:00

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024

GlobeNewswire11/15 21:05

Reported Earlier, 89bio Prices Upsized $125M Public Offering Of 11,455,882 Common Stock At $8.50/Share And Pre-Funded Warrants

Benzinga11/13 15:57

89bio Drops 2%, Prices $125M Stock Offering

Seeking Alpha11/13 14:28

89bio Offering Is Expected to Close Around Nov. 14 >ETNB

Dow Jones11/13 13:02